Estrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Initiating Coverage with a Valuation of $12.00/Share from Zacks Small-Cap Research [Yahoo! Finance]
Arcellx, Inc. (ACLX)
Company Research
Source: Yahoo! Finance
the "Company"), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS ® T-cell therapies to treat cancer and autoimmune diseases, today announced that Zacks Small-Cap Research ("Zacks SCR"), a division of Zacks Investment Research, has initiated coverage on the Company, assigning a valuation of $12.00 per share. The coverage report highlights the Company's differentiated ARTEMIS platform and encouraging early clinical data from the Phase I/II STARLIGHT-1 trial of EB103. "The recent $7.8 billion acquisition of Arcellx by Gilead Sciences underscores the premium that large biopharmaceutical companies continue to place on differentiated cell therapy engineering platforms," said Dr. Cheng Liu, President and Chief Executive Officer of Estrella. "Estrella believes that its ARTEMIS platform, and the early clinical signals observed in STARLIGHT-1, position the Company as a meaningful participant in the next wave of CAR-T innovation." Key Insights from Zacks S
Show less
Read more
Impact Snapshot
Event Time:
ACLX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ACLX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ACLX alerts
High impacting Arcellx, Inc. news events
Weekly update
A roundup of the hottest topics
ACLX
News
- Gilead to buy Ouro Medicines for up to $2.2 billion [Yahoo! Finance]Yahoo! Finance
- Arcellx (ACLX) was upgraded by Truist Financial Corporation from "hold" to "strong-buy".MarketBeat
- $HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger—QETA, NIMU, ACLX, and FONRGlobeNewswire
- This $64 Million Biotech Exit Seemingly Missed a 77% One-Day Surge on Gilead Takeover Deal [Yahoo! Finance]Yahoo! Finance
- Are MASI, ACLX, GLDD Obtaining Fair Deals for their Shareholders?PR Newswire
ACLX
Earnings
- 2/26/26 - Miss
ACLX
Sec Filings
- 3/26/26 - Form SCHEDULE
- 3/19/26 - Form 4
- 3/6/26 - Form SC
- ACLX's page on the SEC website